Physician profile
Soyeun Chu
NPI 1144453473
$1,904.25
in general payments reported to CMS, 2019-2025
15 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $243 · 2021: $280 · 2022: $296 · 2023: $267 · 2024: $167 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $470 · Education: $78.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $470.24 |
| Education | $78.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $618.68 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $392.53 | 2019-2025 | Invega Sustenna |
| Allergan, INC. | $233.88 | 2019 | |
| Abbvie INC. | $188.85 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.74 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $134.71 | 2022-2025 | Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $42.05 | 2022-2023 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $35.17 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.51 | 2021 | |
| Lundbeck LLC | $18.45 | 2020 | |
| Axsome Therapeutics, INC. | $17.84 | 2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $17.38 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.24 | 2022 | |
| Indivior INC. | $13.35 | 2023 | Perseris |
| Jazz Pharmaceuticals INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soyeun Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.